ストックスクリーナーアプリを入手
3.15
1.25%
-0.04
アフターアワーズ：
3.16
0.01
+0.32%
前日終値:
$3.19
開ける：
$3.19
24時間の取引高:
232.78K
Relative Volume:
0.59
時価総額：
$246.10M
収益：
$351.37M
当期純損益:
$-174.01M
株価収益率:
-1.5217
EPS:
-2.07
ネットキャッシュフロー:
$-126.94M
1週間 パフォーマンス:
-0.63%
1か月 パフォーマンス:
-10.00%
6か月 パフォーマンス:
-1.87%
1年 パフォーマンス:
+6.78%
1日の値動き範囲:
$3.14
$3.2265
1週間の範囲:
$3.105
$3.235
52週間の値動き範囲:
$2.455
$4.02
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
AVIR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
3.15 | 249.22M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-13 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-01-06 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-10-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | 開始されました | Evercore ISI | Outperform |
| 2020-11-24 | 開始されました | JP Morgan | Overweight |
| 2020-11-24 | 開始されました | Morgan Stanley | Overweight |
| 2020-11-24 | 開始されました | William Blair | Outperform |
すべてを表示
Atea Pharmaceuticals Inc (AVIR) 最新ニュース
We're Keeping An Eye On Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Rate - Yahoo Finance
How Atea Pharmaceuticals Inc. stock trades during market volatilityTrade Risk Assessment & Community Verified Trade Signals - Newser
Is Atea Pharmaceuticals Inc. stock overvalued by current metricsJuly 2025 Macro Moves & Daily Growth Stock Tips - Newser
How Atea Pharmaceuticals Inc. stock valuations compare to rivalsTake Profit & Fast Entry High Yield Tips - Newser
How Atea Pharmaceuticals Inc. stock performs after earningsJuly 2025 Action & AI Enhanced Trading Signals - Newser
ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman - Stock Titan
Atea Pharmaceuticals director Franklin Berger acquires $81,498 in stock - MSN
Will Atea Pharmaceuticals Inc. stock beat EPS estimatesTrade Risk Report & Expert Approved Momentum Trade Ideas - newser.com
Is Atea Pharmaceuticals Inc. stock reversal real or fake2025 Winners & Losers & Technical Pattern Based Buy Signals - newser.com
Will Atea Pharmaceuticals Inc. stock outperform growth indexesJuly 2025 Action & Momentum Based Trading Ideas - newser.com
How strong is Atea Pharmaceuticals Inc. stock revenue growth2025 Historical Comparison & Growth Focused Investment Plans - newser.com
Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ... By GuruFocus - Investing.com Canada
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference - Yahoo Finance
Is a relief rally coming for Atea Pharmaceuticals Inc. holdersProduct Launch & High Return Trade Opportunity Guides - newser.com
How Atea Pharmaceuticals Inc. stock performs in rate cut cyclesQuarterly Earnings Summary & Reliable Intraday Trade Alerts - newser.com
Atea Pharma (AVIR) Earnings Call Transcript - AOL.com
William Blair Has Negative Outlook of AVIR FY2025 Earnings - Defense World
Atea Pharmaceuticals Inc. stock trend outlook and recovery pathMarket Growth Report & Reliable Price Action Trade Plans - newser.com
Live market analysis of Atea Pharmaceuticals Inc.CEO Change & AI Enhanced Market Trend Forecasts - newser.com
Backtesting results for Atea Pharmaceuticals Inc. trading strategiesJuly 2025 Summary & Real-Time Market Sentiment Reports - newser.com
Atea Pharmaceuticals’ Earnings Call Highlights Progress and Optimism - MSN
Key metrics from Atea Pharmaceuticals Inc.’s quarterly dataMarket Trend Report & Fast Moving Stock Trade Plans - newser.com
What Makes HDFC Mutual fund a Strong Contender in YEAREarnings Call Summaries & Fast Growing Portfolio - earlytimes.in
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2025 Earnings Call Transcript - Insider Monkey
Atea Pharmaceuticals, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:AVIR) 2025-11-14 - Seeking Alpha
Atea Pharmaceuticals Advances Antiviral Programs with New Data - TipRanks
Atea Pharmaceuticals Q3 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Atea Pharmaceuticals Q3 2025 sees EPS miss By Investing.com - Investing.com Nigeria
Atea Pharmaceuticals Inc (AVIR) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):